U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07886268) titled 'A Study to Evaluate the Efficacy and Safety of TP-06 for PCED' on Oct. 05.
Brief Summary: Capellion is a Phase 2 trial comparing TP-06 2.0% with Vehicle in up to 32 adults with persistent corneal epithelial defects. Participants will receive treatment for 8 weeks and be followed for 2 additional weeks to assess corneal healing and safety.
Study Start Date: April 20
Study Type: INTERVENTIONAL
Condition:
Persistent Corneal Epithelial Defect
Intervention:
DRUG: TP-06
TP-06 ophthalmic solution
DRUG: Vehicle of TP-06
Vehicle of TP-06 ophthalmic solution
Recruitment Status: RECRUITING
Sponsor: Tarsus Pharmaceuticals, Inc.
Publ...